Vitality Biopharma is a cure development company, dedicated to unlocking the power of cannabinoids to treat serious neurological and inflammatory disorders.

1. Unlocking the Power of Cannabinoids for Treatment of
Serious Neurological and Inflammatory Conditions

2. Vitality Biopharma has developed a new class of cannabinoid
prodrugs, known as cannabosides, which upon ingestion can
enable the selective delivery of THC and cannabidiol (CBD)
to the gastrointestinal tract.
Site-specific delivery could enable oral drug formulations of
cannabinoids to provide therapeutic benefits while reducing
or avoiding the systemic delivery of THC into the
bloodstream. Currently, high concentrations of psychoactive
THC in the brain limit the dose of cannabinoids that can be
used elsewhere in the body for treatment of pain and
inflammation.

3. In 2013, we developed a proprietary enzymatic biosynthesis
production system in order to improve the taste of stevia, a
natural compound used as a high-potency sweetener. This
platform harnesses a naturally-occurring biological process
known as glycosylation, which involves using enzymes to
attach glucose (sugars) to small-molecule compounds. Over
the last 10 years or so, it has become well appreciated within
the pharmaceutical industry that glycosylation can act to
generate new natural product libraries with improved drug
properties. This platform technology enables us to readily
modify existing drug compounds, especially natural products,
in order to give them attractive new drug properties.

4. Vitality is developing proprietary cannabinoid
pharmaceuticals that are compliant with FDA and DEA
regulations. Oral cannabinoid pharmaceuticals are a
convenient and desirable option for patients and physicians,
and they could help realize the full therapeutic potential of
cannabinoid medicines.

5. Oral prodrugs enable a regulatory strategy with lower risk
that is akin to specialty pharmaceutical development. The
company benefits from existing clinical studies of
cannabinoids demonstrating their effectiveness in treating in
IBD, NBS, MS, neuropathic pain, and additional disease
indications.

6. Senior management is entrepreneurial with a track record in
healthcare and drug development. Laboratory and
manufacturing operations are based in Northern California,
and the R&D team includes passionate scientists, medical
advisers, and regulatory affairs specialists.

7. Clinical Trials & Unmet Needs There is increasing recognition
and acceptance from physicians and researchers that there
may be vast therapeutic potential for cannabinoids, including
THC and also cannabidiol (“CBD”), which is not mind-
altering. This interest has led independent research
investigators to conduct a wide variety of preclinical and
clinical studies to examine their therapeutic benefits,
including for treatment of the disease indications.

8. Independent clinical trial results suggest that cannabinoids
will help induce remission in Crohn’s disease patients, even in
patients who are heavily medicated and have not responded
to corticosteroids, anti-TNF-alpha drugs (Remicade, Humira,
etc.), or immunomodulators.

9. Vitality Biopharma is a cure development company, dedicated
to unlocking the power of cannabinoids to treat serious
neurological and inflammatory disorders.

10. Address: 1901 Avenue of the Stars, 2nd Floor
City: Los Angeles
State: CA
Zip code: 90067
Country: USA
Phone: (530) 231-7800
Email: info@vitality.bio
Website: http://vitality.bio
Web Blog: http://vitality.bio/investors/news/
Twitter: hhttps://twitter.com/VitalityBio
Facebook: https://www.facebook.com/VitalityBio
Linkedin.com: https://www.linkedin.com/company/vitality-biopharma?trk=company_logo